Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma pathways for Low and Middle Income Countries - needed more than ever.

Blood transfusion = Trasfusione del sangue·2026
Same author

Pathogen Reduction of Transfused Blood Components-The End of the Beginning Rather than the Beginning of the End.

Pathogens (Basel, Switzerland)·2026
Same author

United Global Advocacy Drives Updates to World Health Organization Essential Medicines List.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Pathogen Safety Issues Around the "Blood Scandals" 1995-2024-A Perspective Built on Experience.

Pathogens (Basel, Switzerland)·2025
Same author

Commentary: The Infected Blood Inquiry in the United Kingdom-Let the Dust Settle.

Haemophilia : the official journal of the World Federation of Hemophilia·2025
Same author

The past, present and future of blood plasma fractionation.

Biologicals : journal of the International Association of Biological Standardization·2025

Related Experiment Video

Updated: Jun 12, 2026

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)
04:56

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Published on: August 4, 2023

Safety of plasma volume expanders.

Albert Farrugia1

  • 1Plasma Protein Therapeutics Association, 147 Old Solomon's Island Road, Annapolis, MD 21401, USA. afarrugia@pptaglobal.org

Journal of Clinical Pharmacology
|May 27, 2010
PubMed
Summary

Restoring blood volume is critical for treating hypovolemia. This review assesses the safety of plasma expanders like crystalloids and colloids, considering their varied clinical uses and historical safety concerns.

Area of Science:

  • Critical care medicine
  • Pharmacology
  • Physiology

Background:

  • Hypovolemia, a critical condition, necessitates prompt restoration of blood volume and tissue perfusion to prevent severe morbidity and mortality.
  • Intravenous plasma expanders, including crystalloid and colloid solutions, are primary therapeutic agents for managing hypovolemia.
  • A long-standing debate exists regarding the comparative efficacy and safety of crystalloid versus colloid solutions, intensified by concerns over albumin's safety in critically ill patients.

Purpose of the Study:

  • To critically evaluate the safety of various plasma expanding therapies.
  • To examine the safety profiles of crystalloid and colloid solutions across diverse clinical indications.
  • To address the ongoing controversy surrounding plasma expander safety, particularly following influential meta-analyses.

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Related Experiment Videos

Last Updated: Jun 12, 2026

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)
04:56

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Published on: August 4, 2023

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Main Methods:

  • Systematic review of existing literature on plasma expander therapies.
  • Analysis of safety data from clinical trials and meta-analyses concerning crystalloids and colloids.
  • Assessment of safety in relation to specific patient populations and clinical contexts.

Main Results:

  • The safety of plasma expanders is complex and context-dependent, varying with the specific agent and clinical indication.
  • Historical concerns regarding albumin's safety have prompted further research into alternative and safer plasma expansion strategies.
  • Evidence suggests that the choice of plasma expander should be guided by careful consideration of potential risks and benefits for individual patients.

Conclusions:

  • Plasma expander therapy requires a nuanced approach, balancing efficacy with safety across a spectrum of clinical scenarios.
  • Further research is needed to clarify the optimal use of crystalloids and colloids, particularly in vulnerable patient groups.
  • The ongoing evaluation of plasma expander safety is crucial for improving patient outcomes in critical care settings.